The global clinical laboratory tests market size was valued at USD 145.66 billion in 2025 and is projected to grow from USD 155.11 billion in 2026 to USD 256.52 billion by 2034, registering a CAGR of 6.49% during the forecast period from 2026 to 2034. North America dominated the clinical laboratory tests market with a market share of 42.5% in 2025.
Clinical laboratory tests are diagnostic examinations performed on samples such as blood, urine, tissue, and other bodily fluids to detect, diagnose, monitor, or prevent diseases and health conditions. These tests can assess biomarkers, organ function, infections, genetic characteristics, and other health indicators. Clinical laboratory testing plays an important role in healthcare by providing accurate information that helps physicians make informed decisions about patient treatment and disease management.
Download a Free Sample To learn more about this report,
Liquid Biopsy Expands Molecular Testing From Tissue to Blood
Clinical laboratory tests market analysis show that the need for less invasive molecular diagnosis is shifting testing from tissue samples toward circulating cell-free DNA obtained from blood. In May 2026, the FDA approved Guardant360 Liquid CDx, an NGS-based test that analyzes plasma-derived cfDNA and detects genomic alterations across 741 genes for multiple cancer indications. This transition expands laboratory testing options when tissue biopsy is difficult or unavailable and supports biomarker-guided treatment selection.
Rapid Whole-Genome Sequencing Accelerates Rare-Disease Diagnosis
Complex genetic disorders and prolonged diagnostic pathways are shifting clinical laboratories toward rapid whole-genome sequencing as an early diagnostic test. A 2025 study of 322 patients with clinically suspected rare diseases identified causative variants in 138 patients (42.9%), including technically challenging variants that accounted for 21.7% of the diagnostic findings. This transition enables laboratories to detect a broader range of genetic abnormalities within a single testing workflow and can shorten the diagnostic process for patients with unresolved rare diseases.
Chronic Disease Burden and Laboratory Infrastructure Expansion Drive Market
Chronic conditions such as diabetes and chronic kidney disease are creating a sustained demand-side transition toward regular laboratory monitoring. CDC reported in 2026 that about 38% of U.S. adults with diabetes were estimated to have chronic kidney disease, with blood and urine tests used for early detection and monitoring. This recurring testing requirement supports demand for routine biochemical, hematological, and other clinical laboratory services.
A broader laboratory network is creating a supply-side transition toward greater availability of clinical testing services across healthcare settings. CMS reported 302.3 thousand active or certified clinical laboratory providers in Q1 2026, providing extensive infrastructure for test delivery. This network supports wider access to routine and specialized testing and gives laboratories greater capacity to serve expanding diagnostic needs.
Laboratory Skill Shortages and Pricing Pressure Restrain Market Expansion
Shortages of qualified laboratory technologists and specialists can constrain testing capacity and the efficient operation of advanced diagnostic platforms. Workforce gaps can increase turnaround times and restrict laboratories’ ability to expand testing volumes, slowing market adoption and service growth.
Lower reimbursement rates and pricing pressure can reduce the financial returns from routine clinical laboratory testing. Narrower margins can limit investments in equipment, automation, and expanded testing capacity, thereby restraining laboratory service growth.
Laboratory Informatics and Public-Private Partnerships Offer Growth Opportunities
Laboratory software providers and diagnostic companies can capitalize on opportunities in interoperable laboratory information systems, automated reporting, and data analytics. Integrated platforms create revenue avenues through software licensing, implementation, analytics, and managed services, contributing to the clinical laboratory tests market growth.
Private diagnostic laboratories and healthcare service providers can leverage partnerships with hospitals, public health agencies, and healthcare networks for outsourced testing and laboratory management. Long-term service contracts and specialized testing programs create recurring revenue avenues while improving utilization of existing laboratory capabilities.
Diagnostic Supply-Chain Disruptions and Data Interoperability Hinder Growth
Reagent, consumable, and equipment supply disruptions can interrupt testing workflows and make laboratory capacity harder to maintain. A 2025 clinical chemistry review reported that extreme weather events have disrupted laboratory supply chains, specimen transport, and delivery of reagents and equipment, creating operational delays that can hinder market growth.
Fragmented data systems and rising cybersecurity requirements can make secure exchange of laboratory results more complex across laboratories, hospitals, and public-health networks. CDC reported in 2026 that clinical laboratories face growing risks from cyber and physical intrusions into informatics systems, while interoperability initiatives still require substantial technical coordination, which can slow digital expansion and cross-network integration.
The clinical chemistry tests-Basic Metabolic Panel (BMP) segment accounted for a share of 15.2% in 2025, due to its widespread use for assessing glucose, electrolytes, kidney function, and other essential metabolic parameters in routine health evaluations and disease diagnosis.
The molecular diagnostics-next-generation sequencing (NGS) segment is expected to grow at a CAGR of 10.2% during the forecast period 2026-2034, driven by its ability to provide comprehensive genetic analysis, identify disease-associated variants, support precision medicine, and improve the detection of complex conditions. The clinical chemistry tests-Comprehensive Metabolic Panel (CMP) segment, hematology tests-Complete Blood Count (CBC) segment, hematology tests-Coagulation Tests segment, microbiology tests-Culture Tests segment, microbiology tests-Molecular Diagnostics segment, immunology tests-ELISA Tests segment, immunology tests-Western Blot Tests segment, molecular diagnostics-Polymerase Chain Reaction (PCR) segment, urinalysis-Dipstick Tests segment, and urinalysis-Microscopic Examination segment are also expected to support market growth through routine diagnostics, disease screening, infection detection, immune response assessment, and monitoring of patient health.
Request Customizationto receive a tailored report.
The diagnostic laboratories segment accounted for a share of 32.8% in 2025, owing to their extensive role in routine diagnostic testing, disease screening, preventive healthcare, and specialized laboratory services, along with established testing infrastructure and high patient sample volumes.
The diagnostic laboratories segment is expected to grow at a CAGR of 7.4% during the forecast period 2026-2034, fueled by increasing adoption of advanced diagnostic technologies, expanding test menus, greater use of specialized testing, and the growing need for accurate and timely laboratory-based diagnosis. The hospitals-inpatient testing, hospital outpatient testing, and other segments are also expected to support market growth through diagnostic testing across inpatient care, outpatient services, and specialized healthcare settings.
Speak to an Analystto discuss market opportunities.
The North America clinical laboratory tests market accounted for the largest regional share of 42.5% in 2025. Well-established healthcare infrastructure, extensive diagnostic networks, and the integration of laboratory testing into routine clinical care reinforce the region’s leading market position.
The U.S. clinical laboratory tests market benefits from a large and expanding laboratory network, with CMS reporting 301,284 registered laboratories in September 2026, while the Canada clinical laboratory tests market comprised 4,558 medical and diagnostic laboratory establishments in 2025, including 2,429 employer establishments, creating a broad foundation for continued diagnostic testing activity.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific clinical laboratory tests market is expected to grow at a CAGR of 8.3% during the forecast period 2026–2034, showcasing the fastest-growing regional market. Expanding healthcare infrastructure, wider access to diagnostic services, and greater use of advanced laboratory technologies are creating favorable conditions for regional market expansion.
The Japan clinical laboratory tests market reflects sustained diagnostic activity across outpatient and inpatient care, while the China clinical laboratory tests market benefits from an extensive healthcare network that included more than 1.1 million healthcare institutions and 10.65 billion patient visits in 2025; the South Korea clinical laboratory tests market is advancing alongside the country’s expanding health-data and diagnostic infrastructure, and the India clinical laboratory tests market continues to gain from the broadening of laboratory capacity and testing services.
The Europe clinical laboratory tests market accounted for a regional share of 27.8% in 2025. Advanced diagnostic infrastructure, standardized healthcare systems, and a strong focus on laboratory quality and testing accuracy reinforce the region’s established market presence.
Europe’s clinical laboratory tests market is set to benefit from the European Health Data Space, under which the exchange of laboratory results across all EU member states is expected to become operational by March 2031; the U.K. clinical laboratory tests market is gaining capacity through a £237 million investment covering 36 Community Diagnostic Centres, alongside almost 30 million key diagnostic tests performed by the NHS in England in 2025, while the Germany clinical laboratory tests market is positioned to benefit from the country’s aging population and the France clinical laboratory tests market is shaped by the increasing need for diagnostic services associated with demographic aging.
The clinical laboratory tests market is highly fragmented, with independent diagnostic laboratories, hospital-based laboratories, reference laboratories, academic medical centers, and specialized testing providers competing across routine diagnostics, molecular testing, pathology, microbiology, and specialized laboratory services. Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Danaher Corporation, and Thermo Fisher Scientific are among the leading players in the clinical laboratory tests market, collectively accounting for an estimated 45-50% of the global clinical laboratory tests market share. Roche reported CHF 13.85 billion in 2025 diagnostics sales, while Abbott and Danaher reported substantial diagnostics businesses, supporting their prominent positions in the competitive landscape.
Established players compete primarily on test accuracy, service reliability, laboratory scale, test-menu breadth, turnaround time, accreditation, and healthcare-provider networks, while emerging players in the clinical laboratory tests market ecosystem compete through specialized diagnostics, advanced molecular testing, laboratory automation, digital connectivity, decentralized testing, and application-specific solutions. The competitive landscape is also shaped by evolving laboratory standards covering automation, autoverification, connectivity, and information-technology security, reflecting greater emphasis on standardized and integrated testing workflows.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Healthcare Logistics Market Size, Share, Growth, Analysis, 2034
Healthcare Regulatory Affairs Outsourcing Market Size, Share, 2034
Facial Rejuvenation Market Size, Share, Growth, Analysis, 2034
Bioanalytical Testing Services Market Size, Share, Growth, 2034
Medical Device Analytical Testing Outsourcing Market Size, 2034
Long-Term Care Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com